Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regenesis Biomedical, a medical technology company that markets the Provant wound therapy system, has appointed Peter Savas and Chuck Lunden to its board of directors.
Subscribe to our email newsletter
Mr Savas serves as chairman and CEO of Alseres Pharmaceuticals. He holds a bachelor of arts degree in chemistry from Syracuse University.
Mr Lunden is a principal with Bederson and Company, certified public accountant consultants who provide financial and accounting services. Mr Lunden holds a bachelor of science degree in economics from the University of Pennsylvania’s Wharton School of Business.
Virginia Rybski, acting president of Regenesis, said: “We are pleased to welcome these outstanding individuals to our team. Regenesis continues to demonstrate impressive revenue growth, and the perspectives of these individuals will contribute to our ongoing business plan execution.”